Mutation rate in hepatitis C virus NS3 protease is not influenced by HIV-1 protease inhibitor therapy.
Halfon
Philippe
P
Bourlière
Marc
M
Khiri
Hacène
H
Pénaranda
Guillaume
G
Martineau
Agnes
A
Oulès
Valérie
V
Courcambeck
Jérôme
J
Philibert
Patrick
P
D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy*; D016333:HIV Protease; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009154:Mutation; D017361:Viral Nonstructural Proteins / Q000235:genetics*; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases
D016333:HIV Protease; D017320:HIV Protease Inhibitors; D017361:Viral Nonstructural Proteins; C084422:NS3 protein, hepatitis C virus; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases; C514803:p16 protease, Human immunodeficiency virus 1